Antiplatelet and Anticoagulant Medication Usage During Stroke Rehabilitation: The Post-Stroke Rehabilitation Outcomes Project (PSROP)

REFERENCES

• American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, TX: American Heart Association; 2005.
   Google Scholar
• Duncan PW, Homer RD, Reker DM, et al. Adherence to post acute rehabilitation guidelines is associated with functional recovery. Stroke. 2002;33:167–178.
   PubMed Web of Science ®Google Scholar
• Buchanan, JL, Rumpel JD, Hoenig H. Charges for outpatient rehabilitation: growth and differences in provider types. Arch Phys Med Rehabil. 1996; 77:320–328.
   PubMed Web of Science ®Google Scholar
• DeJong G, Horn SD, Conroy B, Nichols D, Healton E. Opening the black box of post-stroke rehabilitation: stroke rehabilitation patients, processes, and outcomes. Arch Phys Med Rehabil. In press.
   Google Scholar
• Roth EJ, Lovell L, Harvey RL, Heinemann, AW, Semik P, Diaz S. Incidence of and risk factors for medical complications during stroke rehabilitation. Stroke. 2001;32:523–529.
   PubMed Web of Science ®Google Scholar
• Joint Commission on Accreditation of Healthcare Organizations. Stroke Disease-Specific Performance Measures. Available at: http://www.jcaho.org/dscc/psc/f_section4_oct04.pdf. Accessed on August 2, 2005.
   Google Scholar
• Commission on Accreditation of Rehabilitation Facilities. Stroke Specialty Programs. Available at: http://www.cartorg/pdf/Stroke_MR.pdf. Accessed on August 3, 2005.
   Google Scholar
• Gassaway J, Horn SD, DeJong G, Smout R, Clark C, James R. Applying the CPI approach to stroke rehabilitation: methods and baseline results. Arch Phys Med Rehabil. In press.
   Web of Science ®Google Scholar
• DeJong G, Horn SD, Gassaway JA, Slavin MD, Dijkers MP. Toward a taxonomy of rehabilitation interventions: using an inductive approach to examine the "black box" of rehabilitation. Arch Phys Med Rehabil. 2004;85(4):678–686.
   PubMed Web of Science ®Google Scholar
• Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:483S–512S.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BM]. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Coull BM, Williams LS, Goldstein LB, et al. Joint Stroke Guideline Development Committee of the American Academy of Neurology; American Stroke Association. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke. 2002;33(7):1934–1942.
   PubMed Web of Science ®Google Scholar
• CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641–1649.
   PubMed Web of Science ®Google Scholar
• The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345–1349.
   PubMed Web of Science ®Google Scholar
• The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–1266.
   PubMed Web of Science ®Google Scholar
• Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Neurol Sci. 1996;143:1–13.
   Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348:1329–1339.
   PubMed Web of Science ®Google Scholar
• EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
   Google Scholar
• Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italian° Fibrillation Atrial) Investigators. Stroke. 1997;28:1015–1021.
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dale JE, Go AS, Haltering IL, Manning WE. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3):4295–4565.
   Google Scholar
• Sabena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. In: The Cochrane Library 2005, Issue 3. Chichester, UK: John Wiley & Sons, Ltd.; 2005.
   Google Scholar
• Mohr JP, Thompson ILP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl I Med. 2001;345:1444–1451.
   PubMed Web of Science ®Google Scholar
• Chimowitz MI. Warfarin vs aspirin for symptomatic intracranial disease (WAIST) [abstract]. Stroke. 2000;31:562.
   Google Scholar
• The ESPRIT Group. Anticoagulation versus aspirin and the combination of aspirin and dipyridamole versus aspirin only in patients with transient ischemic attacks or nondisabling ischemic stroke: ESPRIT (European/Australian Stroke Prevention in Reversible Ischemia Trial). Stroke. 2000;31:557.
   PubMedGoogle Scholar
• Horn SD, ed. Clinical Practice Improvement Methodology: Implementation and Evaluation. New York: Faulkner & Gray; 1997.
   Google Scholar